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Abstract
Chronic obstructive pulmonary disease (COPD) independently associates with an increased risk of coronary artery disease
(CAD), but it has not been fully investigated whether this co-morbidity involves shared pathophysiological mechanisms. To
identify potential common pathways across the two diseases, we tested all recently published single nucleotide
polymorphisms (SNPs) associated with human lung function (spirometry) for association with carotid intima-media
thickness (cIMT) in 3,378 subjects with multiple CAD risk factors, and for association with CAD in a case-control study of
5,775 CAD cases and 7,265 controls. SNPs rs2865531, located in the CFDP1 gene, and rs9978142, located in the KCNE2 gene,
were significantly associated with CAD. In addition, SNP rs9978142 and SNP rs3995090 located in the HTR4 gene, were
associated with average and maximal cIMT measures. Genetic risk scores combining the most robustly spirometry–
associated SNPs from the literature were modestly associated with CAD, (odds ratio (OR) (95% confidence interval
(CI95) = 1.06 (1.03, 1.09); P-value = 1.5610
24, per allele). In conclusion, our study suggests that some genetic loci implicated
in determining human lung function also influence cIMT and susceptibility to CAD. The present results should help elucidate
the molecular underpinnings of the co-morbidity observed across COPD and CAD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a condition
characterised by impaired airflow to the lungs that worsens over
time [1]. The primary risk factor for COPD is long-term exposure
to noxious particles and gases, in particular from cigarette
smoking, which has been shown to trigger inflammation and
abnormal immune responses in the small airways [2]. Local
inflammation in the lung may, in turn, trigger systemic inflam-
matory reactions, such as production of acute-phase proteins in
the liver, with potential adverse consequences for non-respiratory
organs [3]. The incidence proportion of COPD of any severity
grade in smokers reported by observational studies ranges between
15%–40%. The corresponding rates in non-smokers are 8%–15%
[4,5]. As not all smokers contract COPD, it is believed that
susceptibility to COPD is highly variable between individuals, and
that some of the variability may be explained by genetics,
environment and lifestyle, and interactions between these factors
[6].
In pulmonary function testing with spirometry, a reduced
postbronchodilator FEV1/FVC ratio indicates the presence of
airflow limitation and is required for the diagnosis of COPD. To
study the genetic component of COPD, genome-wide association
(GWA) studies have attempted to identify genetic determinants of
human lung function in healthy subjects, using spirometry data on
Forced Expiratory Volume in one second (FEV)1 and its ratio to
Forced Vital Capacity (FVC) (FEV1/FVC). To date, a total of 26
genetic loci for human lung function have been identified, some of
which also seem to be associated with COPD susceptibility, such
as the loci at TNS1, RARB, FAM13A, GSTCD, HHIP,
ADAM19, HTR4, AGER, GPR126, C10orf11 and THSD4
[7,8,9,10,11].
Multiple studies have reported that cardiovascular disease
(CVD), including coronary artery disease (CAD), congestive heart
failure, stroke and peripheral arterial disease, is a major
contributor to mortality and morbidity in COPD. A recent
meta-analysis sought to quantify the CVD risk in COPD using
literature data, and observed a 2–5 fold increased CVD risk in
patients with COPD compared with age- and sex-matched
controls without COPD [12]. The difference persisted after
adjustment for known risk factors. Amongst several possible
explanations for the strong co-morbidity is that COPD and CAD
not only progress in parallel, but also share some common
etiologically relevant biological pathways, involving e.g. oxidative
stress, matrix remodelling and innate and adaptive immune
responses. In the present study, we sought to address this
hypothesis by testing genetic loci for spirometric measures as
determinants for carotid intima-media thickness (cIMT) and
susceptibility to CAD.
Methods
SNP selection
Single nucleotide polymorphisms (SNPs) attaining genome-wide
significance in four recent GWA studies for either FEV1 or the
ratio of FEV1 to FVC [13,14,15,16] were selected for cross-
reference analysis with CAD susceptibility and cIMT. In
particular, we selected 26 lead SNPs, representing 26 loci robustly
associated with spirometry measures, through a literature search
(Table 1).
Association with cIMT measures
The database and biobank of a large, multicenter, European
prospective cohort study (acronym: IMPROVE (Carotid Intima
Media Thickness (IMT) and IMT-PRogression as Predictors of
Vascular Events in a High-Risk European Population) was used
for studying SNP associations with various cIMT measures. The
IMPROVE study was set up for the study of cIMT measures as
predictors of incident coronary events, and enrolled 3,711 subjects
with at least three independent CAD risk factors. Detailed
descriptions of IMPROVE, including the protocols for carotid
ultrasound measures have been reported [17,18]. In the present
study, a total of 3,378 subjects were available for the genetic
association analyses, which included the mean and maximum
IMT of a common carotid segment excluding the first cm
proximal to the bifurcation (CC-IMTmean and CC-IMTmax), mean
and maximum IMT in the internal carotid arteries (ICA-IMTmean
and ICA-IMTmax), and the mean and maximum IMT of the
bifurcation (Bif-IMTmean and Bif-IMTmax). Composite IMT
variables considering the whole carotid tree, derived from the
segment-specific measurements (IMTmean, IMTmax, and IMTmean-
max (the average of IMT maxima recorded at the different
segments)) were also tested for association.
Six of the SNPs had previously been genotyped on the Illumina
CardioMetabochip array. The CardioMetabochip interrogates
<200,000 SNPs located in regions identified by previous GWA
studies of metabolic and cardiovascular traits and diseases. For
eight of the lead SNPs, we selected proxy SNPs (r2$0.85) that
were present on the CardioMetabochip array. Proxies were
selected using SNAP software [19] using 1000 genomes pilot 1
CEU samples as reference. The remaining 12 SNPs were
genotyped with TaqMan probes from Applied Biosystems. Quality
control procedures for the CardioMetabochip array in IMPROVE
have been described [20].
We performed linear regression analyses between the 26 lung
function-associated SNPs and different cIMT measures using
PLINK (v1.07) [21], assuming an additive genetic model and
adjusting for age, gender, body-mass index and the first 3
multidimensional scaling (MDS) dimensions to account for
population stratification (based on CardioMetabochip genotype
data, see details in [20]). All cIMT variables were logarithmically
transformed before statistical analysis because of skewed distribu-
tions. All P-values were Bonferroni-corrected (statistical signifi-
cance set at a P-value#0.00192).
Replication
Replication of the rs3995090 association with cIMT measures
was pursued in the Rotterdam Study (RSI and RSII) and in the
Malmo¨ Diet and Cancer Cohort (MDCC). A description of the
samples used for all analyses is included in Section S1. Only
measures of CC-IMTmean were available in all replication cohorts.
In addition, CC-IMTmax measures were available for RSI and
RSII. Results from the three replication cohorts were meta-
analyzed by using an inverse-variance model with fixed effects as
implemented in METAL [22]. Statistical significance for this SNP
was set at a P-value#0.05.
Association with CAD
We also sought association in silico of the 26 lung function
SNPs with CAD in 5,775 CAD cases and 7,265 controls using
GWA data from the PROCARDIS [23] and Wellcome Trust
Case Control Consortium (WTCCC) collections [24]. Association
was tested by logistic regression analysis assuming an additive
model and adjusting for age, gender, and country using STATA
version 11 ( StataCorp LP, College Station, TX, USA). Since
PROCARDIS contains related individuals (see Section S1),
relatedness was taken into account by setting families as clusters.
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All P-values were Bonferroni-corrected (statistical significance set
at a P-value#0.00192).
Association with Gene Expression
SNP rs3995090 was further analyzed, first with respect to its
association with expression levels of HTR4, and then in relation to
the level of expression of adjacent genes (located within 6500
kilobases (kb) of HTR4) in a secondary extended search, using
data from the Advanced Study of Aortic Pathology (ASAP) and
Biobank of Karolinska Endarterectomies (BiKE) data sets [25]. In
the ASAP study, mRNA was extracted from biopsies of ascending
thoracic aorta intima-media (n = 138), aortic adventitia (n = 133),
mammary artery (n = 89), heart (n = 127), and liver (n = 211) from
patients undergoing aortic valve surgery. In the BiKE study, RNA
was extracted from human plaque tissue (n = 126) and peripheral
blood mononuclear cells (n = 96) from patients referred for surgical
treatment of severe carotid artery stenosis. Associations between
SNP genotype and gene expression level were examined using
additive linear models. Rs3995090 was genotyped in both studies
with the Illumina 610w-Quad BeadArray.
Genetic Risk Scores
We calculated weighted and unweighted genetic risk scores
(GRS) based on the significant SNPs from the FEV1/FVC and
FEV1 GWAs in the literature and used it as a continuous predictor
in logistic/linear regression models with CAD and cIMT-related
phenotypes. Unweighted GRS were built considering the number
of risk alleles, while weighted GRS were built considering the
number of risk alleles weighting them for the beta values reported
in literature. Specifically, the GRS for FEV1/FVC was built on the
following SNPs and beta values (in brackets) derived from
[13,14,15,16]: rs153916 (0.031), rs2277027 (0.045), rs12447804
(0.038), rs2857595 (0.037), rs2070600 (0.088), rs2869967 (0.035),
rs11172113 (0.032), rs12477314 (0.041), rs1690989 (0.059),
rs3817928 (0.05), rs2865531 (0.031), rs7068966 (0.033),
rs2284746 (0.04), rs9978142 (0.043), rs993925 (0.034),
rs1036429 (0.037), rs12899618 (0.06), rs1529672 (0.048),
rs12504628 (0.077) and rs2798641 (0.041). The GRS for FEV1
was built on the following SNPs and beta values: rs2571445
(0.035), rs6903823 (0.037), rs10516526 (0.089), rs3995090 (0.038),
rs11001819 (0.029), rs1344555 (0.034) and rs7068966 (0.029).
Figure S1 shows the frequencies of the number of risk alleles used
to calculate unweighted GRS within PROCARDIS and IM-
PROVE cohorts. Since weighted GRS result from the product of
the number of risk alleles and their effect size, the resulting units
are arbitrary. For the sake of clarity, weighted GRS were divided
in intervals representing total number of possible risk alleles to be
comparable to the ‘‘increased OR per risk allele’’ that was
calculated for the unweighted scores.
Results
Associations with cIMT-related measures
We tested the association between the 26 selected SNPs (or good
proxies) and the different cIMT-associated phenotypes. After
adjustment for age, gender and the first three MDS, a SNP located
in the HTR4 gene (rs3995090) and a proxy for rs2865531 (located
in CFDP1) were found to be consistently associated with several of
the cIMT-associated phenotypes (Table 2, Table S1). The
strongest associations were observed with IMTmean (rs3995090)
and IMTmean-max (rs2865531), both composite cIMT variables
considering the whole carotid tree and derived from the segment-
specific measurements. There was very little change in association
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after further adjustment for smoking (pack-years) (data not shown).
Results stratified by smoking-status are shown in Tables S2–S3.
A regional look-up to assess the association between other SNPs
located in the HTR4 gene (rs10077690, rs17720191, rs11168048,
rs10061244, rs13359903, rs2278392, rs1422636, rs4336354,
rs1833710, rs7700268 and rs888961) did not uncover any other
significant cIMT association within this gene.
Associations were also investigated under a model where all
established CAD risk factors were included, using a stepwise model
in SPSS (using log-transformed IMTmean as phenotype). Altogeth-
er, systolic blood pressure, diastolic blood pressure, waist-hip ratio,
triglycerides, HDL-cholesterol, and LDL-cholesterol explained
7.5% of the variance in this cIMT phenotype, after adjusting for
MDS1–3, age and sex. After adjustment for all these covariates,
rs3995090 and rs2865531 remained significantly associated with
the cIMT phenotypes (Table S4).
GRS-based analyses using the significant SNPs from the FEV1/
FVC and FEV1 GWAs in literature were not significant for
association with cIMT phenotypes (Table S5).
Association with CAD
The minor allele of the SNP located in the CFDP1 gene
(rs2865531T) was associated with a lower risk of CAD
(OR(CI95) = 0.85(0.79–0.92); P-value = 5.36610
25). The minor
allele of the SNP located in KCNE2 (rs9978142T) was associated
with increased risk of CAD (OR(CI95) = 1.22 (1.10, 1.35); P-
value = 1.2361024). In addition, the GRS assessing the global
effect of all the 7 FEV1–robustly associated SNPs from the 4
previous GWAs in literature showed a moderate effect but
significant association with CAD risk, OR(CI95) for weighted
score = 1.05 (1.02, 1.08); P-value = 0.002; OR(CI95) for unweight-
ed score = 1.06 (1.03, 1.09); P-value = 1.561024 per allele).
The GRS assessing the global effect of the 20 FEV1/FVC-
robustly associated SNPs from the 4 previous GWAs in literature
did not prove to be significantly associated with CAD. Association
results for all SNPs is shown in Table S6.
Replication
Among the two spirometry SNPs that showed significant
associations with cIMT measures, rs2865531 has been previously
reported as a determinant of cIMT and CAD risk [20]. Likewise,
the associations between rs9978142 and rs2865533 and CAD
susceptibility were previously established in a large case-control
study of CAD [26]; hence, replication was not pursued.
Therefore, we concentrated further replication efforts on SNP
rs3995090. Replication of rs3995090 was sought in a total of
12,803 individuals with CC-IMTmean and in 6,679 individuals
with CC-IMTmax measures. The rs3995090A allele was associated
with increased CC-IMTmax (beta = 0.006, P-value = 0.044).
Association with gene expression
Expression levels of HTR4 in the heart and vessel wall tissues
were lower than average (below the 30% percentile of all genes). In
peripheral blood mononuclear cells and carotid plaque, the gene
was expressed at the 60% percentile of all genes. SNP rs3995090
was not associated with mRNA expression levels of HTR4 in any
of the tissues tested in the ASAP and BiKE studies, although a
trend was observed in aortic adventitia at P = 0.0826. In a further
expanded search including other neighbouring genes (6500 Kb),
rs3995090 was not associated with mRNA levels of other
neighbouring genes, after multiple-testing correction for 7 genes
in 7 data sets (Table S7).
Discussion
COPD is the fourth largest cause of death worldwide [27]. Co-
morbidities between COPD and other common complex diseases
such as CAD may suggest that shared genetic and/or environ-
mental risk factors exist. Several epidemiologic studies have
suggested before that CAD is a major contributor to mortality and
morbidity in COPD, and that the association between COPD
measures and CAD goes beyond the fact that both diseases share
common environmental risk factors, such as poor diet, sedentary
lifestyle and smoking (reviewed in [28]). Although these studies
cannot demonstrate a causal relationship between COPD and
CAD, strong evidence suggests that the increased systemic
inflammation and oxidative stress associated with COPD contrib-
ute to the increased risk of cardiovascular events, and it is plausible
that multiple other still unknown pathophysiologic pathways may
contribute to the development of both diseases (reviewed in [29]).
In order to explore potential common genetic variants influencing
risk of both COPD and cardiovascular disease, we tested 26 SNPs
with robust association with human lung function for association
with CAD. Since cIMT is considered a robust biomarker for early
atherosclerosis, we also tested these 26 lung function-associated SNPs
with different measures of cIMT. Of note, inverse relationships
between pulmonary function measures adjusted for other risk factors
and cIMT have been found in several studies [30,31,32], indicating
that cIMT may be a robust biomarker for determining cardiovas-
cular morbidity and mortality in COPD [29].
In agreement with our hypothesis that common genetic factors
exist between the COPD and CAD, we found two lung function-
associated SNPs (rs2865531, located in the CFDP1 gene and
rs9978142 located in the KCNE2 gene) that were also associated
with CAD, the minor allele being associated with lower
(rs2865531T) risk and increased risk of CAD (rs9978142T),
respectively. In addition, the latter, along with SNP rs3995090
located in the HTR4 gene, showed strong associations with several
cIMT measures. Finally, a GRS, assessing the global effect of all
the 7 FEV1–associated SNPs from the literature, showed an
association with CAD risk. In all, these results indicate that
common genetic pathways may exist between COPD and cIMT
and CAD, and these are probably independent from the most
classical associated factors, such as systolic blood pressure, diastolic
blood pressure, waist-hip ratio, triglycerides, HDL-cholesterol, and
LDL-cholesterol, since further adjustment for these covariates did
not alter the associations found in the present study.
Among the SNPs associated with both diseases, the SNP located
in KNCE2 (rs9982601, proxy for rs973754 (r2 = 0.81)) has
previously been associated with early-onset myocardial infarction
(MI) in a GWA study of 2,967 cases and 3,075 matched controls
(OR(CI95%) = 1.19 (1.13, 1.27), P = 2610
29) [26]. KNCE2,
located on chromosome 21, codes for a potassium voltage-gated
channel, and mutations in this gene cause inherited arrhythmias
[33]. The rare allele of the SNP located in CFDP1 was recently
found to be associated with higher cIMT measures in a gene-
centric meta-analysis [20]. Interestingly, this SNP was not
associated with expression levels of CFDP1, although a strong
association was found between rs4888378 alleles and expression
levels of a nearby gene (BCAR1), which has been implicated in
cellular adhesion, migration and proliferation/survival of smooth
muscle cells [20,34,35].
Our results for rs3995090, located in the HTR4 region, do not
provide solid evidence of an association with a specific gene. The
SNP is located in HTR4, which is a member of the family of
serotonin receptors. However, expression analyses showed that
there are no allelic-specific differences in the expression of this
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gene by rs3995090 genotype. Other mechanisms might be present
that explain the effect of rs3995090 in HTR4, possibly involving
changes at a protein level. Further studies are needed to elucidate
the role of this SNP.
To the best of our knowledge, this is the first comprehensive
look-up of human lung function robustly-associated loci for
association with CAD and cIMT. Although several epidemiologic
studies have suggested shared pathophysiologic pathways between
both diseases, the present study clearly demonstrates that some
human lung function-associated loci are also associated with CAD
and cIMT. While further functional studies are warranted to
elucidate the role of these genes in the pathophysiology of COPD
and CAD, the overall findings made in this and previous studies
suggest that there are some shared genetic pathways involved in
airway obstruction and cardiovascular risk. This notion opens new
interesting perspectives in understanding the co-morbidity of two
important, common complex diseases.
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